OncoSec Medical (NASDAQ:ONCS) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

OncoSec Medical (NASDAQ:ONCSGet Rating) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02, Fidelity Earnings reports.

NASDAQ ONCS traded down $0.00 during midday trading on Thursday, hitting $0.80. 30,648 shares of the company traded hands, compared to its average volume of 98,086. The company has a market cap of $31.49 million, a PE ratio of -0.77 and a beta of 2.03. The company’s 50-day simple moving average is $0.86 and its 200-day simple moving average is $0.97. OncoSec Medical has a 52 week low of $0.67 and a 52 week high of $4.25.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new stake in shares of OncoSec Medical during the 3rd quarter valued at $53,000. Geode Capital Management LLC lifted its holdings in shares of OncoSec Medical by 33.7% during the 3rd quarter. Geode Capital Management LLC now owns 245,011 shares of the biotechnology company’s stock valued at $521,000 after purchasing an additional 61,689 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of OncoSec Medical during the 3rd quarter valued at $109,000. Renaissance Technologies LLC lifted its holdings in shares of OncoSec Medical by 140.0% during the 4th quarter. Renaissance Technologies LLC now owns 249,361 shares of the biotechnology company’s stock valued at $239,000 after purchasing an additional 145,463 shares during the last quarter. Finally, Susquehanna International Group LLP raised its stake in OncoSec Medical by 62.7% in the 4th quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 16,990 shares during the last quarter. 13.98% of the stock is currently owned by institutional investors and hedge funds.

ONCS has been the topic of several research analyst reports. StockNews.com initiated coverage on OncoSec Medical in a research note on Tuesday. They issued a “sell” rating on the stock. BTIG Research dropped their target price on OncoSec Medical from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th.

About OncoSec Medical (Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Further Reading

Earnings History for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.